Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population

• Published in: Nature medicine Vol. 29; no. 2; pp. 348 - 357
• Main Authors: Lau, Jonathan J., Cheng, Samuel M. S., Leung, Kathy, Lee, Cheuk Kwong, Hachim, Asmaa, Tsang, Leo C. H., Yam, Kenny W. H., Chaothai, Sara, Kwan, Kelvin K. H., Chai, Zacary Y. H., Lo, Tiffany H. K., Mori, Masashi, Wu, Chao, Valkenburg, Sophie A., Amarasinghe, Gaya K., Lau, Eric H. Y., Hui, David S. C., Leung, Gabriel M., Peiris, Malik, Wu, Joseph T.
• Format: Journal Article
• Language: English
• Published: New York Nature Publishing Group US 01.02.2023; Nature Publishing Group
• Subjects: 631/250/590; 631/326/596/4130; 692/699/255/2514; 692/700/478/174; Biomedical and Life Sciences; Biomedicine; BNT162 Vaccine; Cancer Research; Coronaviruses; COVID-19; COVID-19 Vaccines; Effectiveness; Health risks; Humans; Immunization; Infections; Infectious Diseases; Local population; Metabolic Diseases; Molecular Medicine; Neurosciences; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Signs and symptoms; Vaccine Efficacy; Vaccines; Viral diseases; Hong Kong China; China

The SARS-CoV-2 Omicron variant has demonstrated enhanced transmissibility and escape of vaccine-derived immunity. Although first-generation vaccines remain effective against severe disease and death, robust evidence on vaccine effectiveness (VE) against all Omicron infections, irrespective of sympto...